

Help prevent RSV-LRTI

Administer Beyfortus[®] to infants in Hawaii throughout the year^{1,2}

Infants in Hawaii need protection that differs from the typical protection for an RSV season. The pattern of RSV circulation in Hawaii extends from the beginning of August through the end of March, and can vary year to year, with low to moderate incidence even when the season has ended in most of the continental US.^{1,2*}

The Hawaii Department of Health, in collaboration with the CDC and local healthcare providers, recommends year-round administration of Beyfortus²

Beyfortus is available through the Vaccines for Children Program (VFC), Medicaid plans, and most private health insurance plans.^{3†}

IMMUNIZE throughout the
ELIGIBLE INFANTS year with Beyfortus¹

CDC, Centers for Disease Control and Prevention; **RSV-LRTI**, respiratory syncytial virus lower respiratory tract infection.

*In most regions of the US, RSV season typically starts during the fall and peaks in the winter.^{1,4-6}

†Based on available information from national payer organizations.

INDICATION

Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

- Neonates and infants born during or entering their first RSV season.
- Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

IMPORTANT SAFETY INFORMATION

Contraindication

Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Please see additional Important Safety Information on the following page and accompanying full Prescribing Information.

 **Beyfortus[®]** | 50 mg
(nirsevimab-alip) | 100 mg
Injection

Help protect infants against RSV disease with Beyfortus®⁵

IMPORTANT SAFETY INFORMATION (cont'd)

Warnings and Precautions

- **Hypersensitivity Reactions Including Anaphylaxis:** Serious hypersensitivity reactions have been reported following Beyfortus administration. These reactions included urticaria, dyspnea, cyanosis, and/or hypotonia. Anaphylaxis has been observed with human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs and symptoms of anaphylaxis or other clinically significant hypersensitivity reactions occur, initiate appropriate treatment.
- **Use in Individuals with Clinically Significant Bleeding Disorders:** As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

Please see accompanying full Prescribing Information.

Contact your wholesaler or distributor for further details on indirect ordering



References: **1.** Rose EB, Wheatley A, Langley G, et al. Respiratory syncytial virus seasonality—United States, 2014–2017. *MMWR Morb Mortal Wkly Rep*. 2018;67(2):71–76. **2.** Medical advisory: maternal RSV vaccination and infant RSV monoclonal antibody for year-round RSV prevention in infants in Hawaii. State of Hawaii Department of Health. December 27, 2023. Accessed September 24, 2025. <https://health.hawaii.gov/docd/files/2024/08/Medical-Advisory-Infant-RSV-Monoclonal-Antibody-for-Year-Round-RSV-Prevention-in-Infants-in-Hawaii-082324.pdf> **3.** CDC's Vaccines for Children Program addendum: special considerations for COVID-19 vaccine and nirsevimab. Centers for Disease Control and Prevention. Updated March 29, 2024. Accessed September 24, 2025. https://www.cdc.gov/vaccines-for-children/media/pdfs/2024/08/operations-guide-covid-19-addendum-2024-4-2_002-508.pdf **4.** RSV immunization guidance for infants and young children. Centers for Disease Control and Prevention. Updated August 18, 2025. Accessed September 25, 2025. <https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/infants-young-children.html> **5.** Beyfortus (nirsevimab-alip). Prescribing Information. Sanofi. **6.** Immunizations to protect infants. Centers for Disease Control and Prevention. Updated August 18, 2025. Accessed September 24, 2025. <https://www.cdc.gov/rsv/vaccines/protect-infants.html>

sanofi

1 Discovery Drive, Swiftwater, PA 18370
© 2025 Sanofi. All rights reserved.
MAT-US-2511512-v1.0-10/2025

 **Beyfortus®** | 50 mg
(nirsevimab-alip) | 100 mg
Injection